Abstract
Purpose of Review
This review highlights select studies presented at the virtual 2021 European Society of Cardiology (ESC) Congress.
Recent Findings
Reviewed studies assess single photon emission computed tomography, positron emission tomography, magnetic resonance imaging in coronary artery disease (PACIFIC-II); empagliflozin in heart failure with preserved ejection fraction (EMPEROR-Preserved); dapagliflozin in chronic heart failure (DAPA-HF); proprotein convertase subtilisin/kexin type 9 inhibitor and its lipid lowering effects (NATURE-PCSK9); fixed-dose combination therapies with or without aspirin in primary prevention; overview of contrasting results between REDUCE-IT versus STRENGTH trials; Quadruple UltrA-low-dose tReaTment for hypertension (QUARTET); evolocumab and changes in plaque composition on optical coherence tomography (HUYGENS); and low-dose rivaroxaban during the acute phase of acute coronary syndrome (H-REPLACE).
Summary
Research presented at the 2021 ESC Congress shows promise in reducing burden of cardiovascular disease and reinforces the value of cardiovascular disease prevention.
Similar content being viewed by others
Abbreviations
- ABP:
-
Ambulatory blood pressure
- ACS:
-
Acute coronary syndrome
- ASCVD:
-
Atherosclerotic cardiovascular disease
- BP:
-
Blood pressure
- CAC:
-
Coronary artery calcium
- CAD:
-
Coronary artery disease
- CCS:
-
Chronic coronary syndrome
- CCTA:
-
Coronary computed tomography angiography
- CI:
-
Confidence interval
- CRP:
-
C-reactive protein
- CVD:
-
Cardiovascular disease
- DBP:
-
Diastolic blood pressure
- DHA:
-
Docosahexaenoic acid
- ECG:
-
Electrocardiogram
- eGFR:
-
Estimated glomerular filtration rate
- EPA:
-
Eicosapentaenoic acid
- ESC:
-
European Society of Cardiology
- FCT:
-
Fibrous cap thickness
- FDC:
-
Fixed-dose combination
- FFR:
-
Fractional flow reserve
- HF:
-
Heart failure
- HFpEF:
-
Heart failure with preserved ejection fraction
- HFrEF:
-
Heart failure with reduced ejection fraction
- HHF:
-
Hospitalization for heart failure
- HIS:
-
High-intensity statin
- hMBF:
-
Hyperemic myocardial blood flow
- HR:
-
Hazard ratio
- ICA:
-
Invasive coronary angiography
- IVUS:
-
Intravascular ultrasound
- LDL-C:
-
Low-density lipoprotein cholesterol
- MACE:
-
Major adverse cardiac events
- MCE:
-
Major coronary events
- MI:
-
Myocardial infarction
- MPI:
-
Myocardial perfusion imaging
- MRI:
-
Magnetic resonance imaging
- NSTEMI:
-
Non-ST-elevation MI
- OCT:
-
Optical coherence tomography
- OR:
-
Odds ratio
- PCI:
-
Percutaneous coronary intervention
- PCSK9:
-
Proprotein convertase subtilisin/kexin type 9
- RCT:
-
Randomized controlled trial
- RR:
-
Relative risk
- RRR:
-
Relative risk reduction
- SBP:
-
Systolic blood pressure
- SD:
-
Standard deviation
- SPECT:
-
Single photon emission computed tomography
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2107038. In a randomized trial of 5988 heart failure patients with left ventricular ejection fraction >40%, empagliflozin (compared with placebo) was associated with a significant risk reduction in the composite end point of cardiovascular death and first hospitalization for heart failure.
Curtain JP, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Køber L, et al. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J. 2021;42(36):3727–38. https://doi.org/10.1093/eurheartj/ehab560. In a randomized trial of 4,744 heart failure patients with reduced left ventricular ejection fraction, dapagliflozin (compared with placebo) was associated with a significant risk reduction in the composite end point of ventricular arrhythmias and sudden death.
Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: An individual participant data meta-analysis. Lancet. 2021;398(10306):1133–46. https://doi.org/10.1016/S0140-6736(21)01827-4.
Doi T, Langsted A, Nordestgaard BG. A possible explanation for the contrasting results of reduce-it vs. Strength: Cohort study mimicking trial designs. Eur Heart J. 2021. https://doi.org/10.1093/eurheartj/ehab555.
Nicholls SJ, Nissen SE, Prati F, et al. Assessing the impact of pcsk9 inhibition on coronary plaque phenotype with optical coherence tomography: Rationale and design of the randomized, placebo-controlled huygens study. Cardiovasc Diagn Ther. 2021;11(1):120–9 This international double-blind, placebo-controlled randomized controlled trial of 161 patients demonstrated that adding evolucomab to statin therapy among patients after an acute coronary syndrome resulted in a greater increase in minimum fibrous cap thickness and decrease in maximum lipid arc.
Jain V, Al Rifai M, Mahtta D, Liu J, Hussain A, Virani SS. Highlights from studies presented at the virtual american college of cardiology scientific sessions 2021: Staying updated with the latest advancements in prevention. Curr Atheroscler Rep. 2021;23(9):50.
Hussain A, Al Rifai M, Mahtta D, Liu J, Jain V, Virani SS. Highlights from studies presented at the american heart association scientific session 2020: Navigating new roads in prevention. Curr Atheroscler Rep. 2021;23(1):4.
Al Rifai M, Jia X, Al-Mallah MH, Miedema MD, Martin SS, Virani SS. Major randomized clinical trials in cardiovascular disease prevention presented at the 2019 american college of cardiology annual scientific session. Curr Atheroscler Rep. 2019;21(8):31.
Jia X, Al Rifai M, Gluckman TJ, Birnbaum Y, Virani SS. Highlights from selected cardiovascular disease prevention studies presented at the 2019 european society of cardiology congress. Curr Atheroscler Rep. 2019;21(12):46.
Knuuti J, Wijns W, Saraste A, et al. 2019 esc guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–77.
Jones T, Townsend D. History and future technical innovation in positron emission tomography. J Med Imaging (Bellingham). 2017;4(1):011013.
Devine CE, Mawlawi O. Radiation safety with positron emission tomography and computed tomography. Semin Ultrasound CT MR. 2010;31(1):39–45.
Desiderio MC, Lundbye JB, Baker WL, Farrell MB, Jerome SD, Heller GV. Current status of patient radiation exposure of cardiac positron emission tomography and single-photon emission computed tomographic myocardial perfusion imaging. Circ Cardiovasc Imaging. 2018;11(12):e007565.
Mcmurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
Yusuf S, Joseph P, Dans A, et al. Polypill with or without aspirin in persons without cardiovascular disease. N Engl J Med. 2021;384(3):216–28 This meta-analysis of large randomized controlled trials assessed a fixed-dose combination strategy approach of at least 2 BP lowering agents and statin (with or without aspirin) versus a control (placebo or usual care) in a primary cardiovascular disease prevention patient population.
Miedema MD, Huguelet J, Virani SS. Aspirin for the primary prevention of cardiovascular disease: In need of clarity. Curr Atheroscler Rep. 2016;18(1):4.
Miedema MD, Virani SS. Aspirin reduces cardiovascular events in primary prevention of cardiovascular disease but at a near equivalent risk of increased bleeding. Evid Based Med. 2016;21(6):225.
Arnett DK, Blumenthal RS, Albert MA, et al. 2019 acc/aha guideline on the primary prevention of cardiovascular disease: Executive summary: A report of the american college of cardiology/american heart association task force on clinical practice guidelines. Circulation. 2019;140(11):e563–95.
Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295(3):306–13.
Mcneil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379(16):1509–18.
Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22.
Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: The strength randomized clinical trial. JAMA. 2020;324(22):2268–80.
Virani SS, Nambi V, Ballantyne CM. Has the ‘strength’ of fish oil therapy been ‘reduced’? Reconciling the results of reduce-it and strength. Eur Heart J Cardiovasc Pharmacother. 2021;7(3):e7-8.
Chow CK, Gupta R. Blood pressure control: A challenge to global health systems. Lancet. 2019;394(10199):613–5.
Chow CK, Thakkar J, Bennett A, et al. Quarter-dose quadruple combination therapy for initial treatment of hypertension: Placebo-controlled, crossover, randomised trial and systematic review. Lancet. 2017;389(10073):1035–42.
Prati F, Romagnoli E, Gatto L, et al. Relationship between coronary plaque morphology of the left anterior descending artery and 12 months clinical outcome: The clima study. Eur Heart J. 2020;41(3):383–91.
Kataoka Y, Puri R, Hammadah M, et al. Frequency-domain optical coherence tomographic analysis of plaque microstructures at nonculprit narrowings in patients receiving potent statin therapy. Am J Cardiol. 2014;114(4):549–54.
Zou Z, Cini K, Dong B, et al. Time trends in cardiovascular disease mortality across the brics: An age-period-cohort analysis of key nations with emerging economies using the global burden of disease study 2017. Circulation. 2020;141(10):790–9.
Huo Y. Current status and development of percutaneous coronary intervention in china. J Zhejiang Univ Sci B. 2010;11(8):631–3.
Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9–19.
Ohman EM, Roe MT, Steg PG, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to p2y12 inhibition, in acute coronary syndromes (gemini-acs-1): A double-blind, multicentre, randomised trial. Lancet. 2017;389(10081):1799–808.
Funding
This work was supported by a Department of Veterans Affairs Health Services Research & Development Service Investigator Initiated Grant (IIR 16–072), an American Heart Association Beginning Grant-in-Aid (14BGIA20460366), the American Diabetes Association Clinical Science and Epidemiology award (1–14- CE-44), and the Houston VA Health Services Research & Development Center for Innovations grant (CIN13-413). The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs or the US government. The Department of Veterans Affairs or the US government had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Michelle T. Lee, Dhruv Mahtta, Mahmoud Al Rifai, Louis Dlouhy, Hunaina Shahab: None.
Salim S. Virani: Honorarium, American College of Cardiology (Associate Editor for Innovations, acc.org).
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Reviews and New Research Implications
Rights and permissions
About this article
Cite this article
Lee, M.T., Mahtta, D., Dlouhy, L. et al. Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress. Curr Atheroscler Rep 23, 76 (2021). https://doi.org/10.1007/s11883-021-00975-8
Accepted:
Published:
DOI: https://doi.org/10.1007/s11883-021-00975-8